Literature DB >> 15119851

Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.

Monika Sojakova1, Denisa Liptajova, Miroslav Borovsky, Julius Subik.   

Abstract

Vulvovaginal candidiasis is a common mucosal infection caused by opportunistic yeasts of the Candida genus. In this study, we isolated and identified the yeast species in the vagina of patients treated in the gynecology clinic and tested in vitro activities of fluconazole and itraconazole against 227 clinical yeast isolates by the NCCLS microdilution method. C. albicans (87.6%) was the most frequently identified species followed by C. glabrata (6.2%) and C. krusei (2.2%). Almost thirteen percent of yeast strains were resistant to fluconazole and 18.5% were resistant to itraconazole. Cross-resistance analyses of C. albicans isolates revealed that fluconazole resistance and itraconazole resistance were also associated with decreased susceptibilities to other azole derivatives mainly to ketoconazole and miconazole. At the same time no cross-resistance to polyene antibiotics amphotericin B and nystatin was observed. These results support the notion that antifungal agents used to treat vaginitis may be contributing to the drug resistance problem by promoting cross-resistance to a range of clinically used antifungals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15119851     DOI: 10.1023/b:myco.0000020594.35357.b0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  27 in total

Review 1.  Antifungal drug resistance of pathogenic fungi.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

2.  Multiple resistance mechanisms to azole antifungals in yeast clinical isolates.

Authors:  D Sanglard; F Ischer; D Calabrese; M Micheli; J Bille
Journal:  Drug Resist Updat       Date:  1998       Impact factor: 18.500

3.  Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis.

Authors:  E W Cross; S Park; D S Perlin
Journal:  Microb Drug Resist       Date:  2000       Impact factor: 3.431

4.  An investigation into the pathogenesis of vulvo-vaginal candidosis.

Authors:  S S El-Din; M T Reynolds; H R Ashbee; R C Barton; E G Evans
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

5.  Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges.

Authors:  Jack D. Sobel
Journal:  Drug Resist Updat       Date:  1999-06       Impact factor: 18.500

6.  Susceptibility profile of vaginal yeast isolates from Brazil.

Authors:  M A Ribeiro; R Dietze; C R Paula; D A Da Matta; A L Colombo
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

7.  Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

8.  Prevalence of and risk factors for fungal vaginitis caused by non-albicans species.

Authors:  A Spinillo; E Capuzzo; R Gulminetti; P Marone; L Colonna; G Piazzi
Journal:  Am J Obstet Gynecol       Date:  1997-01       Impact factor: 8.661

Review 9.  Mycotic vulvovaginitis: a broad overview.

Authors:  B J Horowitz
Journal:  Am J Obstet Gynecol       Date:  1991-10       Impact factor: 8.661

10.  Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis.

Authors:  A Spinillo; E Capuzzo; S Acciano; A De Santolo; F Zara
Journal:  Am J Obstet Gynecol       Date:  1999-01       Impact factor: 8.661

View more
  18 in total

1.  Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.

Authors:  Carolina Rodrigues Costa; Janine Aquino de Lemos; Xisto Sena Passos; Crystiane Rodrigues de Araújo; Ana Joaquina Cohen; Lúcia Kioko Hasimoto E Souza; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2006-07       Impact factor: 2.574

2.  Detection of FUR1 Gene in 5-Flucytosine Resistant Candida Isolates in Vaginal Candidiasis Patients.

Authors:  Sasikala Gopinathan; Anand B Janagond; David Agatha; Thenmozhivalli P R
Journal:  J Clin Diagn Res       Date:  2013-11-10

3.  Oxidative stress response and virulence factors in Candida glabrata clinical isolates.

Authors:  N Berila; P Hyroššová; J Subík
Journal:  Folia Microbiol (Praha)       Date:  2011-03-18       Impact factor: 2.099

4.  Molecular analysis of Candida glabrata clinical isolates.

Authors:  Norbert Berila; Julius Subik
Journal:  Mycopathologia       Date:  2010-03-17       Impact factor: 2.574

5.  Evaluation of antifungal activity of medicinal plant extracts against oral Candida albicans and proteinases.

Authors:  José Francisco Höfling; Rita Cássia Mardegan; Paula Cristina Anibal; Vivian Fernandes Furletti; Mary Ann Foglio
Journal:  Mycopathologia       Date:  2011-03-16       Impact factor: 2.574

6.  Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.

Authors:  Shu-Hua Ge; Zhe Wan; Juan Li; Jianping Xu; Ruo-Yu Li; Feng-Yan Bai
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

Review 7.  Two cases of vaginitis caused by itraconazole-resistant Saccharomyces cerevisiae and a review of recently published studies.

Authors:  Vincenzo Savini; Chiara Catavitello; Assunta Manna; Marzia Talia; Fabio Febbo; Andrea Balbinot; Francesco D'Antonio; Giovanni Di Bonaventura; Claudio Celentano; Marco Liberati; Raffaele Piccolomini; Domenico D'Antonio
Journal:  Mycopathologia       Date:  2008-04-29       Impact factor: 2.574

8.  Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.

Authors:  B Minea; V Nastasa; R F Moraru; A Kolecka; M M Flonta; I Marincu; A Man; F Toma; M Lupse; B Doroftei; N Marangoci; M Pinteala; T Boekhout; M Mares
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-16       Impact factor: 3.267

9.  In vivo activity of Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida species.

Authors:  Edílson Damke; Joyce K Tsuzuki; Diógenes A G Cortez; Izabel C P Ferreira; Thâmara A Bertoni; Márcia R Batista; Lucélia Donati; Terezinha I E Svidzinski; Márcia E L Consolaro
Journal:  BMC Complement Altern Med       Date:  2011-05-04       Impact factor: 3.659

10.  A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination In Vitro Susceptibilities of Isolated Fungal Strains to Conventional and New Antifungals.

Authors:  Samaneh Halvaee; Roshanak Daie-Ghazvini; Seyed Jamal Hashemi; Sadegh Khodavaisy; Abbas Rahimi-Foroushani; Heidar Bakhshi; Zahra Rafat; Pegah Ardi; Mahdi Abastabar; Mahdi Zareei; Zeinab Borjian-Boroujeni; Hasti Kamali Sarvestani
Journal:  Front Cell Infect Microbiol       Date:  2021-07-15       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.